Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Real tACS | Experimental | Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus) |
|
| Sham tACS | Placebo Comparator | Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gamma tACS (40 Hz) over the superior parietal cortex | Device | Single session of gamma tACS (40 Hz) over the superior parietal cortex |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Rey Auditory Verbal Learning Test score | Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes. The examiner reads aloud 15 unrelated words and the participant is asked to recall the words after each of the five trials. After a 15 minute delay, the participant is asked again to recall the words. The score ranges from 0 (worst performance) to 75 (best performance). | Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention |
| Changes in Rey Auditory Verbal Learning Test, recognition | Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. After a 15 minute delay, the participant is asked to recognise the original 15 words intermixed with 31 distractor words. The score of the recognition part ranges from 0 (worst performance) to 46 (best performance). | Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention |
| Changes in orientation to time and place (MMSE questions 1-10) | 10 questions about the orientation. The score ranges from 0 (worse performance) to 10 (best performance). | Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention |
| Changes in Trail Making A & B tests | TMT A & B tests. Time to perform set is recorded. | Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention |
| Changes in INECO Frontal Screening test |
| Measure | Description | Time Frame |
|---|---|---|
| Change in SAI measurements | By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic neurotransmission. | Baseline (immediately before the intervention), immediately after the last intervention |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Eino Solje, MD, PhD | Contact | +358 17 713 311 | eino.solje@uef.fi |
| Name | Affiliation | Role |
|---|---|---|
| Eino Solje, MD, PhD | Kuopio University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kuopio University Hospital | Recruiting | Kuopio | Finland |
Pseudonymized data upon request, according to Finnish national and EU GDPR regulations
Not provided
Data will be shared after the study completion indefinitely.
Reasonable request
Not provided
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D057180 | Frontotemporal Dementia |
| D020961 | Lewy Body Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Test battery assessing frontal lobe functions. The score ranges from 0 (worse performance) to 30 (best performance) |
| Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention |
| Changes in phonemic fluency | Person is requested to provide as many words as possible starting with certain letter. The score is the sum of all acceptable words produced in one minute. | Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention |
| Change in SICI measurements |
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short interval intracortical inhibition (SICI), which is a marker of gabaergic neurotransmission. |
| Baseline (immediately before the intervention), immediately after the last intervention |
| Change in ICF measurements | By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on intracortical facilitation (ICF), which is a marker of glutamatergic neurotransmission. | Baseline (immediately before the intervention), immediately after the last intervention |
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D057174 | Frontotemporal Lobar Degeneration |
| D057177 | TDP-43 Proteinopathies |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |